[{"address1": "535 W 24th Street", "address2": "5th Floor", "city": "New York", "state": "NY", "zip": "10011", "country": "United States", "phone": "(855) 508-3568", "website": "https://www.neurogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.", "fullTimeEmployees": 91, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel L. McMinn Ph.D.", "age": 50, "title": "Founder, Executive Chair & CEO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 676542, "exercisedValue": 0, "unexercisedValue": 203486}, {"maxAge": 1, "name": "Ms. Christine Mikail Cvijic J.D.", "age": 45, "title": "President, CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 623289, "exercisedValue": 0, "unexercisedValue": 658819}, {"maxAge": 1, "name": "Dr. Stuart  Cobb Ph.D.", "age": 53, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 478807, "exercisedValue": 0, "unexercisedValue": 338906}, {"maxAge": 1, "name": "Mr. Arvind  Sreedharan", "title": "Senior Vice President of Business Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Donna M. Cochener-Metcalfe J.D.", "age": 48, "title": "Senior VP & General Counsel", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Effie  Albanis M.D.", "title": "Senior Vice President of Early Clinical & Translational Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew E. Mulberg CPI, FAAP, M.D.", "title": "Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ricardo  Jimenez", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julie  Jordan M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1719619200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 34.82, "open": 34.95, "dayLow": 33.96, "dayHigh": 37.13, "regularMarketPreviousClose": 34.82, "regularMarketOpen": 34.95, "regularMarketDayLow": 33.96, "regularMarketDayHigh": 37.13, "forwardPE": -8.4627905, "volume": 1545882, "regularMarketVolume": 1545882, "averageVolume": 121593, "averageVolume10days": 273810, "averageDailyVolume10Day": 273810, "bid": 36.21, "ask": 36.85, "bidSize": 200, "askSize": 100, "marketCap": 472353120, "fiftyTwoWeekLow": 12.2, "fiftyTwoWeekHigh": 53.0, "fiftyDayAverage": 33.9438, "twoHundredDayAverage": 26.788725, "currency": "USD", "enterpriseValue": 317227712, "floatShares": 6170700, "sharesOutstanding": 12980300, "sharesShort": 1060958, "sharesShortPriorMonth": 997788, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0817, "heldPercentInsiders": 0.12777, "heldPercentInstitutions": 0.94047, "shortRatio": 14.51, "shortPercentOfFloat": 0.091400005, "impliedSharesOutstanding": 12980300, "bookValue": 13.279, "priceToBook": 2.740417, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 8996000, "trailingEps": -3.19, "forwardEps": -4.3, "pegRatio": -0.33, "lastSplitFactor": "1:4", "lastSplitDate": 1702944000, "enterpriseToEbitda": -5.477, "52WeekChange": 1.2054546, "SandP52WeekChange": 0.22553468, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NGNE", "underlyingSymbol": "NGNE", "shortName": "Neurogene Inc.", "longName": "Neurogene Inc.", "firstTradeDateEpochUtc": 1394202600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "51d6a4c2-efb6-34ae-b4ed-f6ab994594b8", "messageBoardId": "finmb_602062523", "gmtOffSetMilliseconds": -14400000, "currentPrice": 36.39, "targetHighPrice": 65.0, "targetLowPrice": 44.0, "targetMeanPrice": 51.8, "targetMedianPrice": 51.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 169532992, "totalCashPerShare": 13.061, "ebitda": -57923000, "totalDebt": 14408000, "quickRatio": 14.395, "currentRatio": 14.735, "debtToEquity": 8.437, "returnOnEquity": -0.30419, "operatingCashflow": -59517000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-30"}]